Improvements in Glycemic Outcomes in 4738 Children, Adolescents, and Adults with Type 1 Diabetes Initiating a Tubeless Insulin Management System.
CSII
HbA1c
Insulin pumps
Insulin therapy
Real-world outcomes
Type 1 diabetes
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
28
09
2022
accepted:
09
01
2023
pubmed:
11
2
2023
medline:
11
2
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
Despite recent advances in diabetes technology, most people living with type 1 diabetes mellitus (T1D) are unable to meet glycemic targets. Real-world evidence can provide insight into outcomes achieved with specific treatment devices when used in clinical practice. The aim of this study was to analyze real-world outcomes collected from a large cohort of people living with T1D and initiating treatment with the Omnipod DASH System. In this retrospective observational study, real-world outcomes were analyzed from a database of information collected from people with T1D initiating the Omnipod DASH System. Information in the database was either taken directly from the patient's medical record or self-reported if medical records were unavailable. The primary outcome was change in glycated hemoglobin (HbA1c) from baseline (before initiation) to 3 months after initiation. Secondary outcomes were changes in total daily dose of insulin (TDD) and self-reported frequency of hypoglycemic events (< 70 mg/dL). Results are separated for the adult (≥ 18 years, N = 3341) and pediatric (< 18 years, N = 1397) cohorts. The change in HbA1c from baseline was - 0.9 ± 1.6% ( - 10 ± 18 mmol/mol; p < 0.0001) in adults and - 0.9 ± 2.0% ( - 10 ± 22 mmol/mol; p < 0.0001) in the pediatric cohort. For those previously using multiple daily injections, HbA1c decreased by - 1.0 ± 1.7% ( - 11 ± 19 mmol/mol) in adults and - 1.0 ± 2.1% ( - 11 ± 23 mmol/mol) in the pediatric cohort (both p < 0.0001). Hypoglycemic events decreased in adults from 2.9 to 1.3 episodes per week ( - 1.6 ± 3.2 events/week; p < 0.0001), and in the pediatric cohort from 2.8 to 1.5 episodes per week ( - 1.3 ± 2.7 events/week; p < 0.0001). In adults, TDD decreased by 19.9% (p < 0.0001), and it remained stable in the pediatric cohort (p > 0.05). Real-world outcomes from this large cohort of people initiating therapy with the Omnipod DASH System showed significant improvement in HbA1c and a substantial reduction in hypoglycemic events after 3 months of use.
Identifiants
pubmed: 36763329
doi: 10.1007/s13300-023-01366-9
pii: 10.1007/s13300-023-01366-9
pmc: PMC9913031
doi:
Types de publication
Journal Article
Langues
eng
Pagination
593-610Informations de copyright
© 2023. The Author(s).
Références
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.
Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep. 2013;13(6):795–804.
Lawrence JM, Divers J, Isom S, Saydah S, Imperatore G, Pihoker C, et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001–2017. JAMA. 2021;326(8):717–27.
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66–72.
Mauras N, Mazaika P, Buckingham B, Weinzimer S, White NH, Tsalikian E, et al. Longitudinal assessment of neuroanatomical and cognitive differences in young children with type 1 diabetes: association with hyperglycemia. Diabetes. 2015;64(5):1770–9.
Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, et al. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes? J Diabetes Complications. 2018;32(10):911–5.
Baxter M, Hudson R, Mahon J, Bartlett C, Samyshkin Y, Alexiou D, et al. Estimating the impact of better management of glycaemic control in adults with type 1 and type 2 diabetes on the number of clinical complications and the associated financial benefit. Diabet Med. 2016;33(11):1575–81.
Diabetes Control Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England J Med. 1993;329(14):977–86.
Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–18.
Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, et al. Impact of type 1 diabetes in the developing brain in children: a longitudinal study. Diabetes Care. 2021;44(4):983–92.
Jaser SS, Jordan LC. Brain health in children with type 1 diabetes: risk and protective factors. Curr Diab Rep. 2021;21(4):12.
Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477–86.
American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of medical care in diabetes—2022. Diabetes Care. 2021;45(Suppl 1):S97–S112.
Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology—continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3922–37.
Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609–52.
Grunberger G, Bailey TS, Cohen AJ, Flood TM, Handelsman Y, Hellman R, et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on Insulin Pump Management. Endocr Pract. 2010;16(5):746–62.
Sundberg F, Barnard K, Cato A, de Beaufort C, DiMeglio LA, Dooley G, et al. ISPAD guidelines. Managing diabetes in preschool children. Pediatr Diabetes. 2017;18(7):499–517.
Messer LH, Tanenbaum ML, Cook PF, Wong JJ, Hanes SJ, Driscoll KA, et al. Cost, hassle, and on-body experience: barriers to diabetes device use in adolescents and potential intervention targets. Diabetes Technol Ther. 2020;22(10):760–7.
doi: 10.1089/dia.2019.0509
pubmed: 32163719
Perez-Nieves M, Garey C, Fan L, McAuliffe-Fogarty AH. Insulin pump therapy—patient and provider perceptions. Diabetes. 2018;67(Suppl 1):981–P.
Taleb N, Messier V, Ott-Braschi S, Ardilouze JL, Rabasa-Lhoret R. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: results of an online survey. Diabetes Res Clin Pract. 2018;144:42–50.
Tanenbaum ML, Adams RN, Hanes SJ, Barley RC, Miller KM, Mulvaney SA, et al. Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use. J Diabetes Sci Technol. 2017;11(3):484–92.
doi: 10.1177/1932296816688010
pubmed: 28745093
pmcid: 5505431
Reidy C, Bracher M, Foster C, Vassilev I, Rogers A. The process of incorporating insulin pumps into the everyday lives of people with type 1 diabetes: a critical interpretive synthesis. Health Expect. 2018;21(4):714–29.
Commissariat PV, Boyle CT, Miller KM, Mantravadi MG, DeSalvo DJ, Tamborlane WV, et al. Insulin pump use in young children with type 1 diabetes: sociodemographic factors and parent-reported barriers. Diabetes Technol Ther. 2017;19(6):363–9.
Zisser HC. The OmniPod Insulin Management System: the latest innovation in insulin pump therapy. Diabetes Ther. 2010;1(1):10–24.
doi: 10.1007/s13300-010-0004-6
pubmed: 22127670
pmcid: 3118276
Ly TT, Layne JE, Huyett LM, Nazzaro D, O’Connor JB. Novel bluetooth-enabled tubeless insulin pump: innovating pump therapy for patients in the digital age. J Diabetes Sci Technol. 2019;13(1):20–6.
doi: 10.1177/1932296818798836
pubmed: 30239214
Brown RE, Vienneau T, Aronson R. Canadian real-world outcomes of omnipod initiation in people with type 1 diabetes (COPPER study): evidence from the LMC Diabetes Registry. Diabet Med. 2020;38(6):e14420.
Mehta SN, Tinsley LJ, Kruger D, Bode B, Layne JE, Huyett LM, et al. Improved glycemic control following transition to tubeless insulin pump therapy in adults with type 1 diabetes. Clinical Diabetes. 2021;39(1):72–9.
Leelarathna L, Roberts SA, Hindle A, Markakis K, Alam T, Chapman A, et al. Comparison of different insulin pump makes under routine care conditions in adults with type 1 diabetes. Diabet Med. 2017;34(10):1372–9.
Layne JE, Parkin CG, Zisser H. Efficacy of the omnipod insulin management system on glycemic control in patients with type 1 diabetes previously treated with multiple daily injections or continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2016;10(5):1130–5.
Danne T, Schwandt A, Biester T, Heidtmann B, Rami-Merhar B, Haberland H, et al. Long-term study of tubeless insulin pump therapy compared to multiple daily injections in youth with type 1 diabetes: Data from the German/Austrian DPV Registry. Pediatr Diabetes. 2018;19(5):979–84.
Biester T, Schwandt A, Heidtmann B, Rami-Merhar B, Haak T, Festa A, et al. Declining frequency of acute complications associated with tubeless insulin pump use: data from 2,911 patients in the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry. Diabetes Technol Ther. 2021;23(8):527–36.
Carlson AL, Huyett LM, Jantz J, Chang A, Vienneau T, Ly TT. Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system. Diabetes Res Clin Pract. 2021;174: 108735.
Layne JE, Parkin CG, Zisser H. Efficacy of a tubeless patch pump in patients with type 2 diabetes previously treated with multiple daily injections. J Diabetes Sci Technol. 2017;11(1):178–9.
Pillalamarri SS, Huyett LM, Abdel-Malek A. Novel bluetooth-enabled tubeless insulin pump: a user experience design approach for a connected digital diabetes management platform. J Diabetes Sci Technol. 2018;12(6):1132–42.
doi: 10.1177/1932296818804802
pubmed: 30304951
pmcid: 6232743
Carlson AL, Huyett LM, Jantz J, Chang A, Vienneau T, Ly TT. Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system. Diabetes Res Clin Pract. 2021;174:108735.
Sherr JL. Closing the loop on managing youth with type 1 diabetes: children are not just small adults. Diabetes Care. 2018;41(8):1572–8.
Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–80.
Lee JM, Carlson E, Albanese-O’Neill A, Demeterco-Berggren C, Corathers SD, Vendrame F, et al. Adoption of telemedicine for type 1 diabetes care during the COVID-19 pandemic. Diabetes Technol Ther. 2021;23(9):642–51.
Garg SK, Rodbard D, Hirsch IB, Forlenza GP. Managing new-onset type 1 diabetes during the COVID-19 pandemic: challenges and opportunities. Diabetes Technol Ther. 2020;22(6):431–9.
American Diabetes Association Professional Practice Committee. 6. Glycemic targets: standards of medical care in diabetes—2022. Diabetes Care. 2021;45(Suppl 1):S83–S96.
Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care. 1996;19(4):324–7.
Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev. 2006;22(3):232–7.
Sherr J, Tamborlane WV. Past, present, and future of insulin pump therapy: better shot at diabetes control. Mt Sinai J Med. 2008;75(4):352–61.
doi: 10.1002/msj.20055
pubmed: 18729180
pmcid: 2562271
Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765–74.
Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51(6):941–51.
doi: 10.1007/s00125-008-0974-3
pubmed: 18351320
Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010(1):CD005103.
Pickup JC. Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol. 2012;8(7):425–33.
doi: 10.1038/nrendo.2012.28
pubmed: 22371161
Steineck I, Cederholm J, Eliasson B, Rawshani A, Eeg-Olofsson K, Svensson AM, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350: h3234.
Rosenlund S, Hansen TW, Andersen S, Rossing P. Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study. Diabet Med. 2015;32(11):1445–52.
doi: 10.1111/dme.12950
pubmed: 26331364
Beato-Vibora P, Yeoh E, Rogers H, Hopkins D, Amiel SA, Choudhary P. Sustained benefit of continuous subcutaneous insulin infusion on glycaemic control and hypoglycaemia in adults with type 1 diabetes. Diabet Med. 2015;32(11):1453–9.
Albanese-O’Neill A, Grimsmann JM, Svensson AM, Miller KM, Raile K, Akesson K, et al. Changes in HbA1c between 2011 and 2017 in Germany/Austria, Sweden, and the United States: a lifespan perspective. Diabetes Technol Ther. 2022;24(1):32–41.
Hermann JM, Miller KM, Hofer SE, Clements MA, Karges W, Foster NC, et al. The transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV Registry. Diabet Med. 2020;37(5):848–55.
Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59(1):87–91.
Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324(7339):705.
Paldus B, Lee MH, O’Neal DN. Insulin pumps in general practice. Aust Prescr. 2018;41(6):186–90.
doi: 10.18773/austprescr.2018.056
pubmed: 30670886
pmcid: 6299172
McAdams BH, Rizvi AA. An overview of insulin pumps and glucose sensors for the generalist. J Clin Med. 2016;5(1):5.
doi: 10.3390/jcm5010005
pubmed: 26742082
pmcid: 4730130
Berget C, Messer LH, Forlenza GP. A clinical overview of insulin pump therapy for the management of diabetes: past, present, and future of intensive therapy. Diabetes Spectr. 2019;32(3):194–204.
doi: 10.2337/ds18-0091
pubmed: 31462873
pmcid: 6695255
Klonoff DC, Reyes JS. Insulin pump safety meeting: summary report. J Diabetes Sci Technol. 2009;3(2):396–402.
doi: 10.1177/193229680900300224
pubmed: 20144372
pmcid: 2771530
Zhang Y, Jones PL, Klonoff DC. Second insulin pump safety meeting: summary report. J Diabetes Sci Technol. 2010;4(2):488–93.
doi: 10.1177/193229681000400232
pubmed: 20307411
pmcid: 2864186
Gradel AKJ, Porsgaard T, Lykkesfeldt J, Seested T, Gram-Nielsen S, Kristensen NR, et al. Factors affecting the absorption of subcutaneously administered insulin: effect on variability. J Diabetes Res. 2018;2018:1205121.
doi: 10.1155/2018/1205121
pubmed: 30116732
pmcid: 6079517